Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to evaluate the safety and effectiveness of an investigational/experimental drug called AIR001. To test the effectiveness, the study will evaluate how AIR001 affects the blood vessels in the lungs and…
- Trial name
- NCT01725256
- Testing
- AIR001 (sodium nitrite inhalation solution)
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 29 people
- Sponsor
- Aires Pharmaceuticals, Inc.
Pulmonary Arterial Hypertension
Apabetalone for Pulmonary Arterial Hypertension
Throughout the past twenty years, numerous specific pharmacologic agents targeting the endothelial dysfunction associated with PAH have emerged.
- Trial name
- APPROACH-2 (NCT04915300)
- Testing
- Apabetalone
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Laval University
Hypertension, Pulmonary
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934) will be asked to participate in this long term extension study with BAY63-2521.
- Trial name
- PATENT-2 (NCT00863681)
- Testing
- Riociguat (BAY63-2521)
- Where
- 99 sites in United States, Argentina and 25 more
- Volunteers
- 396 people
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension
: Vascular Function in Health and Disease
Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions.
- Conditions
- Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
- Trial name
- NCT02966665
- Testing
- Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123
- Where
- United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- D. Walter Wray
Pulmonary Arterial Hypertension
Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)
The objectives of the RELIEVE-PAH study are to obtain first-in-human experience with the study device in patients with severe pulmonary arterial hypertension, including evidence of initial safety, device performance and possible…
- Trial name
- RELIEVE-PAH (NCT03838445)
- Testing
- V-Wave Interatrial Shunt
- Where
- 3 sites in United States, Mexico
- Volunteers
- 9 people
- Sponsor
- V-Wave Ltd
Portopulmonary Hypertension, Pulmonary Arterial Hypertension (PAH)
Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension
Congenital portosystemic shunt (CPSS) are rare vascular malformations causing blood from the intestines to bypass the liver and directly flow into body's general circulation.
- Conditions
- Portopulmonary Hypertension, Pulmonary Arterial Hypertension (PAH), Congenital Portosystemic Shunt
- Trial name
- Gen-PoPH-CPSS (NCT07314814)
- Testing
- targeted gene panels analysis, whole genome analysis
- Where
- Switzerland
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Prof. Valérie Mc Lin
Back Pain, Coronary Artery Disease
Detecting and Addressing Preclinical Disability
The Physical Functioning Inventory (PFI) is a standardized patient reported outcome measure that assesses preclinical disability.
- Conditions
- Back Pain, Coronary Artery Disease, Chronic Obstructive Pulmonary Disease, Diabetes
- Trial name
- NCT01979081
- Testing
- Tailored advice from a physiotherapist and/or an occupational therapist through the myOSCAR patient portal
- Where
- Canada
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- McMaster University
Pulmonary Hypertension
To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks
The purpose of this study is to provide sildenafil therapy to eligible adult patients with pulmonary arterial hypertension (PAH) and to the patients who completed the A1481142 study for the treatment of PAH in Poland.
- Trial name
- NCT00946114
- Testing
- sildenafil
- Where
- 2 sites in Poland
- Volunteers
- 32 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
COMPression of Left Main coRonary artEry in patientS With Pulmonary Arterial Hypertension aSymptomatIc fOr aNgina
The prevalence of critical ab extrinsic compression of left main coronary artery (LMCA) is very high in patients with pulmonary arterial hypertension (PAH) symptomatic for angina (up to 40% according to a recent study of 121…
- Trial name
- COMPRESSION (NCT05413109)
- Testing
- Coronary CT angiography
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Pulmonary Arterial Hypertension
PET/MRI in PAH Patients
Aim of the study is to compare novel parameters of right ventricle (RV) function from right heart catheterization (RHC) and magnetic resonance imaging (MRI) with PET-derived RV FDG uptake.
- Trial name
- NCT03688698
- Testing
- PET/MRI
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Medical University of Bialystok
Pulmonary Artery Hypertension
Evaluation of Respiratory Muscle in Patient With Pulmonary Arterial Hypertension
The aim of the study is that evaluation of basic and accessory respiratory muscles and their relationship of six minute walk test in patient with pulmonary arterial hypertension (PAH)
- Trial name
- NCT05056532
- Testing
- patient assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Giresun University
Pulmonary Hypertension
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the efficacy and safety of vardenafil in the treatment of pulmonary arterial hypertension.
- Trial name
- EVALUATION (NCT00718952)
- Testing
- Vardenafil
- Where
- 10 sites in China
- Volunteers
- 60 people
- Sponsor
- Tongji University
Hypertension, Pulmonary
Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects
GlaxoSmithKline (GSK) is embarking on a clinical program to assess the treatment of PAH with an Angiotensin converting enzyme 2 (ACE2).
- Trial name
- NCT03304548
- Testing
- Telephone concept elicitation interview
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
Remodulin® to Oral Treprostinil Transition
This multi-center, open-label study will assess the tolerability and safety of transitioning subjects with stable Pulmonary Arterial Hypertension (PAH) from continuous intravenous (IV) or subcutaneous (SC) Remodulin infusion to…
- Trial name
- NCT01588405
- Testing
- UT-15C SR
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension
FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- NCT00760916
- Testing
- UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg
- Where
- 31 sites in United States, Australia and 1 more
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension, Systemic Sclerosis
A Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic Sclerosis
This protocol is of a systematic review for risk factors of pulmonary arterial hypertension in systemic sclerosis.
- Trial name
- NCT03889509
- Where
- Canada
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor…
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Connective Tissue Diseases
- Trial name
- Xenon PAH Bio (NCT06104228)
- Testing
- 129Xe Hyperpolarized
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Bastiaan Driehuys
Pulmonary Arterial Hypertension
The Effect of Adding Exercise Training to Optimal Therapy in PAH
Exercise capacity (EC) is limited in pulmonary arterial hypertension (PAH) by impaired right ventricular (RV) function and inability to increase stroke volume (SV). Disease targeted therapy, increases EC by improving SV.
- Trial name
- NCT02961023
- Testing
- Exercise therapy
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- National Health Service, United Kingdom
Pulmonary Arterial Hypertension
Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
The study was conducted as a placebo-controlled, randomized, 22-week double-blind study which included a dose titration period. An additional transition period occurred for those patients who elected to enroll into the open-label…
- Trial name
- NCT02279160
- Testing
- APD811
- Where
- 35 sites in United States, Australia and 7 more
- Volunteers
- 61 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Pulmonary Hypertension Association Registry
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
- Conditions
- Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
- Trial name
- PHAR (NCT04071327)
- Where
- 52 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Pulmonary Hypertension Association, Inc.